吡西卡尼 盐酸盐

C₁₇H₂₄N₂O · xHCl

272.39 (free base basis)

MFCD00903769

329819981

Pilsicainide hydrochloride has been used as a sodium channel blocker:

• to study its effects on electrophysiological parameters in guinea pig pulmonary vein preparation
• to study its effects on Ca²⁺ release and arrhythmic events in Andersen-Tawil syndrome induced pluripotent stem cells (ATS-iPSC)-derived cardiomyocytes
• to study its electrophysiological effects on the guinea pig atrium

Pilsicainide hydrochloride is a pure sodium channel blocker and an open channel blocker of Na⁺¹ channels. Pilsicainide was defined as a pure sodium channel blocker. The compound is classified as a class Ic antiarrhythmic drug, and was originally developed in Japan. Similar to Lidocaine, Pilsicainide binds to open channels, but slowly. Pilsicainide is capable of selectively blocking the late currents in the mutant Na(⁺) channels that show dominant abnormal burst openings such as in δKPQ mutants. The compound is used to induce Brugada syndrome (BS) in animal models.

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

100

≥98% (HPLC)

powder

white to beige

deionized water: >5 mg/mL

room temp

Cl.Cc1cccc(C)c1NC(=O)CC23CCCN2CCC3

1S/C17H24N2O.ClH/c1-13-6-3-7-14(2)16(13)18-15(20)12-17-8-4-10-19(17)11-5-9-17;/h3,6-7H,4-5,8-12H2,1-2H3,(H,18,20);1H

NZOSVDHCTCLGEB-UHFFFAOYSA-N

10, 50 mg in glass bottle

GHS07

Warning

H302

Acute Tox. 4 Oral

11 - Combustible Solids

WGK 3